Skip to main content
. 2015 Aug 7;7(6):1045–1057. doi: 10.1080/19420862.2015.1076600

Figure 3.

Figure 3.

Pareto optimal variants, trading off HSC score and energy at a range of mutational loads from predecessor sequences. (A) anti-CD30 (AC10); (B) anti-EGFR (Ab 225); (C) trastuzumab; (D) bevacizumab; (E) alemtuzumab. All humanized designs generated have energies that are better than or only marginally higher than the predecessor sequences.